Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Syndax Pharmaceuticals, Inc. (SNDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
1Distinct source URLs
9High confidence
0.801Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Syndax Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
UCB-BIOPHARMA-SRL
UCB-BIOPHARMA-SRL
92%
In 2016, the Company entered into a license agreement, or the UCB License Agreement, as amended from time to time, with UCB Biopharma Sprl, or UCB, under which UCB granted to the Company a worldwide,…
the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events or certain termination events with respect to the Company’s license agreement wit…
Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events…
VITAE-LICENSE-AGREEMENT
VITAE-LICENSE-AGREEMENT
85%
As of the date of the Vitae License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility
Reciprocal relationship from ATNM graph: eferred to and treated in comprehensive treatment centers for in-patient treatment as opposed to community, outpatient-based care. As a result, we believe the…
Reciprocal relationship from INCY graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from INCY graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from INCY g…
Syndax Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
REVUFORJ
REVUFORJ
80%
We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab
NIKTIMVO
NIKTIMVO
75%
the first United States sale of Revuforj in its second indication
COMPANY-LLC
COMPANY-LLC
62%
iscussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Results of Operations Comparison of t…
LYMPHOMA-GROUP
LYMPHOMA-GROUP
62%
approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weig…
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC
62%
y any amounts out of accumulated other comprehensive gain for the same periods. The following table summarizes the available-for-sale securities: Amortized Unrealized Unrealized Cost Gains Losses Fai…
Syndax Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SNDX-DEBT-12638
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-12-31.
SNDX-DEBT
Debt stack $344.0M
90%
Market cache reports total debt of $344.0M.
SNDX-DEBT-12637
Warrants outstanding: 0.0001
90%
xbrl warrant detail from xbrl 2019-03-31.
Syndax Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Syndax Pharmaceuticals, Inc..
Syndax Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
SNDX-OWNER-GOLDMAN-SACHS-GROUP-INC
GOLDMAN SACHS GROUP INC
90%
13F overlay lists GOLDMAN SACHS GROUP INC as top holder; 246 tracked holders.
Syndax Pharmaceuticals, Inc. Extended Supply Chain Network
